For the first time ever, the Food & Drug Administration has approved a medication specifically for treating postpartum depression.
The drug is called Brexanolone, and is administered through an intravenous infusion that takes nearly three days.
It will be sold under the name Zulresso.
In clinical trials, it was shown to work within hours to treat symptoms of postpartum depression.
One out of nine new mothers experience postpartum depression after they give birth.
The side effects of the new treatment were found to be mild, but the treatment itself is time-consuming and expensive.
(This story was originally published on March 20, 2019)